Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Trading update

4 May 2010 15:07

RNS Number : 2913L
CareCapital Group plc
04 May 2010
 



04 May 2010

 

CARECAPITAL GROUP PLC

("CareCapital" or "the Company")

 

Financial Close of Project

£4.5 million Development of Allesley Park Community Centre, Coventry

 

CareCapital plc (AIM: CARE), the healthcare real estate developer and owner, is pleased to announce the completion of contract and funding arrangements for the development of a new Community Centre, with a total floor area of 2,555 square meters, located in Allesley Park, Coventry. The Centre will comprise a public library of 405 square meters, a medical centre of 844 square meters, a pharmacy of 154 square meters and community/medical services areas of 779 square meters. Construction is expected to commence in early July 2010 with completion in August 2011. Total expected development cost for the entire project will be £4.5 million.

 

The library is being funded by Coventry City Council and the medical centre and pharmacy by Primary Health Properties PLC (under a pre-sale framework agreement announced on 8 February 2010). The Company will fund, and retain for letting, the community/medical services areas for £ 600,000 from its existing financial resources. CareCapital will act as developer for the whole project and will provide facilities management for the completed building.

 

Commenting on the project close, Paul Stacey, Chief Executive of CareCapital, said, "This is a landmark project for the City of Coventry and for CareCapital which will provide much needed community and medical services and will enable us to deliver a valuable asset let to long term high quality tenants."

 

For further information please visit www.carecapital.co.uk or contact:

 

CareCapital Group Plc

Daniel Stewart & Co. Plc

Tavistock Communications

Paul Stacey, Chief Executive

Simon Leathers

Simon Hudson

Paul Young

Tel: 020 7034 1949

Tel: 020 7776 6550

Tel: 020 7920 3150

pstacey@carecapital.co.uk

simon.leathers@danielstewart.co.uk

shudson@tavistock.co.uk

pyoung@tavistock.co.uk

 

~ ends ~

 

 

Notes to Editors

 

CareCapital is a developer and investor in primary healthcare real estate, partnering GPs, dentists and other clinical providers - in the UK and Germany - to develop uniquely tailored, cost-effective and sustainable care facilities. CareCapital has a current portfolio value of £39.9 million (as at 31 December 2007).

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSSIFLLFSSESI
Date   Source Headline
27th Aug 20197:00 amRNSTotal Voting Rights and Directors' Shareholdings
8th Aug 201910:45 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Nearing the end-goal
7th Aug 20197:00 amRNSIssue of equity and new debt facility
6th Aug 201911:05 amRNSSecond Price Monitoring Extn
6th Aug 201911:00 amRNSPrice Monitoring Extension
25th Jul 20195:12 pmRNSResult of AGM
25th Jul 20197:00 amRNSAGM Statement & Technological update
22nd Jul 20197:00 amRNSHarley Street update
28th Jun 20197:00 amRNSFinal Results
3rd Jun 20197:00 amRNSTechnological update
31st May 20195:30 pmRNSTotal Voting Rights
17th May 20195:29 pmRNSHolding(s) in Company
16th May 20192:23 pmEQSAdvanced Oncotherapy (AVO-GB): Strong fundamentals underpin future growth
13th May 201912:20 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Commercialising a breakthrough technology
10th May 20197:00 amRNSDebt facility secured
16th Apr 201910:26 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Preparing for commercialisation
16th Apr 20199:12 amEQSAdvanced Oncotherapy (AVO-GB): Key talent acquisition reaffirms the promise of LIGHT
16th Apr 20197:00 amRNSSenior Management Appointment
7th Mar 20199:00 amRNSPrice Monitoring Extension
22nd Feb 20197:00 amRNSGrant of options
1st Feb 20197:00 amRNSAppointment of Nominated Adviser and Joint Broker
30th Jan 201911:45 amRNSSchedule 2(g) Disclosure
29th Jan 20199:38 amRNSTotal Voting Rights and Significant Shareholdings
24th Jan 201912:14 pmRNSSchedule 2(g) Disclosure
22nd Jan 20193:29 pmRNSResult of General Meeting
21st Jan 201911:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Important regulatory milestone: ISO approval
21st Jan 20197:00 amRNSISO 13485:2016 certification for medical devices
21st Dec 201810:15 amRNSLaunch of 2018 SAYE Scheme
21st Dec 20187:00 amRNSProposed Direct Subscription to raise £10.0m
16th Oct 20184:31 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Four components integrated
16th Oct 20183:58 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
10th Oct 20187:30 amRNSGPSL Research - Flash Note on AVO
10th Oct 20187:00 amRNSTechnological update
4th Oct 201811:07 amRNSGPSL Research - Flash Note on AVO
28th Sep 20187:00 amRNSHalf-year Report
27th Sep 20187:00 amRNSTechnological update
10th Sep 201811:32 amRNSHolding(s) in Company
7th Sep 201811:52 amRNSHolding(s) in Company
3rd Sep 20185:15 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
3rd Sep 201811:38 amRNSCompletion of the £6.41m Placing
29th Aug 20189:57 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
28th Aug 20187:00 amRNSDirector Declaration
9th Aug 20187:00 amRNSExercise of Warrants and Issue of Shares
2nd Aug 20187:00 amRNS£6.41m Placing
25th Jul 20183:34 pmRNSResult of AGM
4th Jul 20184:40 pmRNSSecond Price Monitoring Extn
4th Jul 20184:35 pmRNSPrice Monitoring Extension
4th Jul 201811:05 amRNSSecond Price Monitoring Extn
4th Jul 201811:00 amRNSPrice Monitoring Extension
4th Jul 20189:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.